Journal News

Antibodies inhibit hyperactive protein disposal

Emily Ulrich
June 12, 2025

A system of ubiquitin-associated enzymes marks misfolded or needless proteins for degradation to maintain protein homeostasis, but its dysfunction can lead to disease. Hyperactivation of the E3 ubiquitin ligase carboxyl-terminus of Hsp70-interacting protein, or CHIP, is linked to cystic fibrosis, neurodegeneration and cancer. Scientists confront numerous challenges when attempting to inhibit CHIP due to its complex interaction network with E2 ubiquitin-conjugating enzymes and chaperones, so that CHIP can orchestrate ubiquitin transfer to the substrate. CHIP has a dimeric structure and uses its tetratricopeptide repeat, or TPR, domain to bind chaperones and a U-box domain to bind the E2 enzyme.

In a recent Journal of Biological Chemistry article, Dong hee Chung, Emily Connelly and a team at the University of California, San Francisco, used a biopanning platform for screening inhibitors of CHIP. This technique involved a phage display library of fragment antigen-binding antibodies, or Fabs, segments of a full antibody able to penetrate tissues, and rounds of filtering for CHIP binders. The researchers identified six Fabs for further characterization.

The authors performed fluorescence polarization assays to examine whether the Fabs inhibited binding of a model peptide substrate to the CHIP TPR domain. They also assessed the ability of each Fab to inhibit Hsp70 chaperone ubiquitination by CHIP. The Fab 2F1 stood out because of its strong inhibition of both peptide binding and Hsp70 ubiquitination. Using cryogenic electron microscopy, the researchers determined that two 2F1 molecules bind to the CHIP dimer, one at each U-box domain.

The authors suggested that 2F1 and the other Fabs in this study will provide useful tools for scientists to probe the various CHIP domains and substrate interactions. Inhibiting individual aspects of CHIP function will also help scientists gauge the value of CHIP as a potential drug target.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is ASBMB’s former science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Unraveling the language of histones
Profile

Unraveling the language of histones

Nov. 20, 2025

Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
News

How Alixorexton could transform narcolepsy treatment

Nov. 18, 2025

A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.

Phosphatases and pupils: A dual legacy
Profile

Phosphatases and pupils: A dual legacy

Nov. 13, 2025

Yale professor Anton Bennett explores how protein tyrosine phosphatases shape disease, while building a legacy of mentorship that expands opportunity and fuels discovery in biochemistry and molecular biology.

Extracellular vesicles offer clues to cattle reproduction
Journal News

Extracellular vesicles offer clues to cattle reproduction

Nov. 11, 2025

Extracellular vesicles from pregnant cattle support embryo development better than laboratory models, highlighting their potential to improve reproductive efficiency in bovine embryo cultures. Read more about this recent MCP paper.

Proteomics reveals protein shifts in diabetic eye disease
Journal News

Proteomics reveals protein shifts in diabetic eye disease

Nov. 11, 2025

Using proteomics, researchers identified protein changes in eye fluid that mark diabetic retinopathy progression and may serve as biomarkers for vision-threatening complications. Read more about this recent MCP paper.

Protein modifications drive lung cancer resistance
Journal News

Protein modifications drive lung cancer resistance

Nov. 6, 2025

New assay enriches protein modifications in a single process, enabling detection of key changes in drug-resistant lung cancer cells that may guide future therapies.